The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Cougar-02: A randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma.
Natalie Cook
No relevant relationships to disclose
Andrea Marshall
No relevant relationships to disclose
Jane M. Blazeby
No relevant relationships to disclose
John A. Bridgewater
No relevant relationships to disclose
Jonathan Wadsley
No relevant relationships to disclose
Fareeda Y. Coxon
No relevant relationships to disclose
Wasat Mansoor
No relevant relationships to disclose
Srinivasan Madhusudan
No relevant relationships to disclose
Stephen Falk
No relevant relationships to disclose
Gary William Middleton
Consultant or Advisory Role - Sanofi
Daniel Swinson
No relevant relationships to disclose
Ian Chau
Consultant or Advisory Role - Sanofi
Joyce Thompson
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Santhera
Paula Kareclas
No relevant relationships to disclose
Janet A. Dunn
No relevant relationships to disclose
Hugo Ford
Research Funding - Sanofi